Phase 2 study of the efficacy and safety of ponsegromab in patients with cancer cachexia: PROACC‐1 study design

• Päätekijät: John D. Groarke (Tekijä), Jeffrey Crawford (Tekijä), Susie M. Collins (Tekijä), Shannon L. Lubaczewski (Tekijä), Danna M. Breen (Tekijä), Magdalena A. Harrington (Tekijä), Ira Jacobs (Tekijä), Ruolun Qiu (Tekijä), James Revkin (Tekijä), Michelle I. Rossulek (Tekijä), Aditi R. Saxena (Tekijä)
• Aineistotyyppi: Kirja
• Julkaistu: Wiley, 2024-06-01T00:00:00Z.
• Aiheet: article
• Linkit: Connect to this object online.

Abstract Background Cancer cachexia is a multifactorial metabolic wasting syndrome characterized by anorexia, unintentional loss of weight involving both skeletal muscle and adipose tissues, progressive functional impairment and reduced survival. Therapeutic strategies for this serious condition are...